Tatsunori Sakamoto

Prof. Tatsunori Sakamoto

Shimane University Faculty of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KMKenji Mizuseki
Kenji Mizuseki
TSTatsunori Sakamoto
Tatsunori Sakamoto
KWKiichi Watanabe
Kiichi Watanabe
KMKeiko Muguruma
Keiko Muguruma
MIMakoto Ikeya
Makoto Ikeya
YSYoshiki Sasai
Yoshiki Sasai
To understand the range of competence of embryonic stem (ES) cell-derived neural precursors, we have examined in vitro differentiation of mouse and primate ES cells into the dorsal- (neural crest) and ventralmost (floor plate) cells of the neural axis. Stromal cell-derived inducing activity (SDIA; accumulated on PA6 stromal cells) induces cocultured ES cells to differentiate into rostral CNS tissues containing both ventral and dorsal cells. Although early exposure of SDIA-treated ES cells to bone morphogenetic protein (BMP)4 suppresses neural differentiation and promotes epidermogenesis, late BMP4 exposure after the fourth day of coculture causes differentiation of neural crest cells and dorsalmost CNS cells, with autonomic system and sensory lineages induced preferentially by high and low BMP4 concentrations, respectively. In contrast, Sonic hedgehog (Shh) suppresses differentiation of neural crest lineages and promotes that of ventral CNS tissues such as motor neurons. Notably, high concentrations of Shh efficiently promote differentiation of HNF3β + floor plate cells with axonal guidance activities. Thus, SDIA-treated ES cells generate naïve precursors that have the competence of differentiating into the “full” dorsal–ventral range of neuroectodermal derivatives in response to patterning signals.

24 October 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TITakatoshi Inaoka
Takatoshi Inaoka
HSHirofumi Shintaku
Hirofumi Shintaku
Takayuki NakagawaTakayuki Nakagawa
Takayuki Nakagawa
SKSatoyuki Kawano
Satoyuki Kawano
HOHideaki Ogita
Hideaki Ogita
JIJuichi Ito
Juichi Ito
Cochlear hair cells convert sound vibration into electrical potential, and loss of these cells diminishes auditory function. In response to mechanical stimuli, piezoelectric materials generate electricity, suggesting that they could be used in place of hair cells to create an artificial cochlear epithelium. Here, we report that a piezoelectric membrane generated electrical potentials in response to sound stimuli that were able to induce auditory brainstem responses in deafened guinea pigs, indicating its capacity to mimic basilar membrane function. In addition, sound stimuli were transmitted through the external auditory canal to a piezoelectric membrane implanted in the cochlea, inducing it to vibrate. The application of sound to the middle ear ossicle induced voltage output from the implanted piezoelectric membrane. These findings establish the fundamental principles for the development of hearing devices using piezoelectric materials, although there are many problems to be overcome before practical application.

25 November 2010 in BMC Medicine
Verified
Journal Article
Open access
PDF file
Takayuki NakagawaTakayuki Nakagawa
Takayuki Nakagawa
TSTatsunori Sakamoto
Tatsunori Sakamoto
HHHarukazu Hiraumi
Harukazu Hiraumi
YKYayoi S Kikkawa
Yayoi S Kikkawa
NYNorio Yamamoto
Norio Yamamoto
JIJuichi Ito
Juichi Ito
Sudden sensorineural hearing loss (SSHL) is a common condition in which patients lose the hearing in one ear within 3 days. Systemic glucocorticoid treatments have been used as standard therapy for SSHL; however, about 20% of patients do not respond. We tested the safety and efficacy of topical insulin-like growth factor 1 (IGF1) application using gelatin hydrogels as a treatment for SSHL. Patients with SSHL that showed no recovery to systemic glucocorticoid administration were recruited. We applied gelatin hydrogels, impregnated with recombinant human IGF1, into the middle ear. The primary outcome measure was the proportion of patients showing hearing improvement 12 weeks after the test treatment. The secondary outcome measures were the proportion of patients showing improvement at 24 weeks and the incidence of adverse events. The null hypothesis was that 33% of patients would show hearing improvement, as was reported for a historical control after hyperbaric oxygen therapy. In total, 25 patients received the test treatment at a median of 23 days (range 15-32) after the onset of SSHL, between 2007 and 2009. At 12 weeks after the test treatment, 48% (95% CI 28% to 69%; P = 0.086) of patients showed hearing improvement, and the proportion increased to 56% (95% CI 35% to 76%; P = 0.015) at 24 weeks. No serious adverse events were observed. Topical IGF1 application using gelatin hydrogels is well tolerated and may be efficacious for hearing recovery in patients with SSHL that is resistant to systemic glucocorticoids.

19 November 2014 in BMC Medicine
Verified
Journal Article
Open access
PDF file
Takayuki NakagawaTakayuki Nakagawa
Takayuki Nakagawa
KKKozo Kumakawa
Kozo Kumakawa
SUShin-ichi Usami
Shin-ichi Usami
NHNaohito Hato
Naohito Hato
KTKeiji Tabuchi
Keiji Tabuchi
JIJuichi Ito
Juichi Ito
To date, no therapeutic option has been established for sudden deafness refractory to systemic corticosteroids. This study aimed to examine the efficacy and safety of topical insulin-like growth factor-1 (IGF-1) therapy in comparison to intratympanic corticosteroid therapy. We randomly assigned patients with sudden deafness refractory to systemic corticosteroids to receive either gelatin hydrogels impregnated with IGF-1 in the middle ear (62 patients) or four intratympanic injections with dexamethasone (Dex; 58 patients). The primary outcome was the proportion of patients showing hearing improvement (10 decibels or greater in pure-tone average hearing thresholds) 8 weeks after treatment. The secondary outcomes included the change in pure-tone average hearing thresholds over time and the incidence of adverse events. In the IGF-1 group, 66.7% (95% confidence interval [CI], 52.9-78.6%) of the patients showed hearing improvement compared to 53.6% (95% CI, 39.7-67.0%) of the patients in the Dex group (P = 0.109). The difference in changes in pure-tone average hearing thresholds over time between the two treatments was statistically significant (P = 0.003). No serious adverse events were observed in either treatment group. Tympanic membrane perforation did not persist in any patient in the IGF-1 group, but did persist in 15.5% (95% CI, 7.3-27.4%) of the patients in the Dex group (P = 0.001). The positive effect of topical IGF-1 application on hearing levels and its favorable safety profile suggest utility for topical IGF-1 therapy in patients with sudden deafness. UMIN Clinical Trials Registry Number UMIN000004366 , October 30th, 2010.

23 September 2009 in NeuroReport
Verified
Journal Article
Closed access
KNKoji Nishimura
Koji Nishimura
TNTakayuki Nakagawa
Takayuki Nakagawa
KOKazuya Ono
Kazuya Ono
HOHideaki Ogita
Hideaki Ogita
TSTatsunori Sakamoto
Tatsunori Sakamoto
JIJuichi Ito
Juichi Ito
This study examined the potential of induced pluripotent stem (iPS) cells for use as a source of transplants for the restoration of auditory spiral ganglion neurons. We monitored neurite outgrowth from iPS cell-derived neural progenitors toward cochlear hair cells ex vivo, and followed their survival and fates after transplantation into mouse cochleae in vivo. Neurons derived from iPS cells projected neurites toward cochlear hair cells. The settlement of iPS cell-derived neurons was observed 1 week after transplantation into the cochlea. Some transplants expressed vesicular glutamate transporter 1, which is a marker for glutamatergic neurons. These findings indicate that iPS cells can be used as a source of transplants for the regeneration of spiral ganglion neurons.

3 December 2007 in NeuroReport
Verified
Journal Article
Closed access
RHRyusuke Hori
Ryusuke Hori
TNTakayuki Nakagawa
Takayuki Nakagawa
TSTatsunori Sakamoto
Tatsunori Sakamoto
YMYoshinori Matsuoka
Yoshinori Matsuoka
STShinji Takebayashi
Shinji Takebayashi
JIJuichi Ito
Juichi Ito
Recent studies using explant cultures have demonstrated that pharmacological inhibition of Notch signaling by γ-secretase inhibitors generates supernumerary hair cells in embryonic or neonatal cochleae. The aim of this study was to examine the effects of such pharmacological inhibition on mature auditory epithelia in vivo. Normal adult guinea pig auditory epithelia exhibited weak or no immunoreactivity for Notch1 and Jagged1, whereas ototoxic treatment caused the upregulation of these molecules in damaged auditory epithelia. Local application of a γ-secretase inhibitor in damaged cochleae generated ectopic hair cells in mature auditory epithelia. These findings indicate that pharmacological inhibition of Notch signaling is a possible strategy for hair cell regeneration in adult auditory epithelia.